Rabindra Shivnaraine, Director of Clinical Pharmacology at Aerys Biosciences, attended the 2026 J.P. Morgan Healthcare Conference in San Francisco.
Aerys Biosciences is advancing innovative, first-in-class, disease-modifying therapies for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).